Notable Labs, Ltd. · OTC:NTBLQ
Notable Labs — Merger or Acquisition (October 2023)
22 slides from Notable Labs's merger presentation, Oct 16, 2023
Slide 1: Focusing Precision on Patient Outcomes
PPMP — Predictive Precision medicine Platform Focusing Precision on Patient Outcomes … October 2023
Slide 2: Forward Looking Statements
Forward Looking Statements: This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding Notable Labs’ (“Notable”) future operat
Slide 3: Notable Summary
Notable Summary • Clinical-stage therapeutic platform company headquartered in Foster City, CA • PPMP: Proprietary platform predicts clinical response to treatment* • Merges biology & technology innovation (incl. AI/machine learning) • 97% response rate across 4 clinical validation trials (no need f
Slide 4: Notable's PPMP Addresses An Urgent Need across Oncology
Notable’s PPMP Addresses An Urgent Need across Oncology Treatment Limitation Huge Benefit For Responders but Few Treated Patients Respond 1,000,000s OF 1,000s OF 100s OF Treated Patients Compelling Drugs Promising Candidate Drugs Without Benefit Shelved Struggling Solution Higher Response Rates Pred
Slide 5: PPMP: Demonstrated High Predictive Precision
PPMP Demonstrated High Predictive Precision PPMP 100 Predicts Patient Response 97% 80 Response 60 Rate* 40 • Bio-simulates treatment • Measures cell response 20 • Applies AI/ML algorithms • Unconfined by genomic markers 0 Validated against Actual Patient Responses 5 *Average response rate (RR) acros
Slide 6: PPMP: 97% RR across Clinical Validation Trials
PPMP: 97% RR across Clinical Validation Trials Response Rates* 100% 83% 100% 100% 100% Predicted Responder Clinical Clinical Non-responder Responder Stanford MD Anderson Texas Children’s Washington Washington University1 Cancer Center2 Hospital3 University4 University4 Myelodysplastic Acute Myeloid
Slide 7: Vision: Better, Predictable Outcomes. Simpler Practice.
PPMP Vision: Better, Predictable Outcomes. Simpler Practice. Today* PPMP* Yes No Page 5/10 Treatment Options Treatment Options *Concept of clinical settings in which today’s treatment options deliver low response rates. Notable drug’s response rate refers to PPMP-predicted responders.
Slide 8: PPMP Strategy: Target, Boost & Fast-Track
PPMP Strategy: Target, Boost & Fast-Track In-License Shelved Drugs (compelling efficacy + low RR): Maximize Return + Minimize Risk • Boost phase 3 drug to market-leading RR • Fast-track in predicted responders Deliver Highest RR Co-Develop Active Precision Drugs (proven class + low/moderate RR) For
Slide 9: PPMP Strategy Boosts Proven Model
PPMP Strategy Boosts Proven MODEL PPMP PPMP Scalability Model: SieRRA Oncology* Upside Drug by Drug, Value X Disease by Disease Creation Shelved + revived hematology drug, 30% RR* + Responder Selection Higher RR → Lower Risk → Higher Speed → New Patent Purchase Sale Drug (Cash) Company 9 *https://en
Slide 10: PPMP Focuses Biology & Technology on Response
PPMP FocusES Biology & Technology on Response Bio Biological targeting (Precision Medicine) Focus Outcomes Validation Bio-Simulation Response High RR YES Tech vs. vs. vs. Molecular aberrations Often low RR with genomic markers Often non-validated targets (PM*, AI Drug Design) (PM) (PM, AI Drug Desig
Slide 11: PPMP Makes Treatment Decisions Simpler
PPMP Makes Treatment Decisions Simpler Patient Treatment Predicted Actual Actual Sample Bio-Simulation Responder treatment responDER + →YES + No Actionable Yes/No in 3 Days 11
Slide 12: PPMP Merges Biology & Technology
PPMP Merges Biology & Technology Patient Treatment Predicted Sample Bio-Simulation Responder + →YES No Bio-ASSAy conditions Bio-Response Measures Computed Algorithms 12
Slide 13: AI/ML Continually Advance Performance
AI/ML Continually Advance performance Patient Treatment Predicted Actual Actual Sample Bio-Simulation Responder treatment responDER + →YES + No AI/ML Learning Loop World’s Largest Cancer Bio-Response Database (Hematology) 190 billion lines of Notable data 13
Slide 14: PPMP Plan: Start in Leukemia. Expand Broadly.
PPMP Plan: Start in LeuKemia. Expand Broadly. Leverage Approved Drugs ✓ In-License Shelved Drugs 1. Map best opportunities 2. Expand PPMP ✓ • Pharma Partnerships • Drug by drug (>150 incl. combinations) (1,000+ drugs screened) Co-Develop Novel PMs • Cancer by cancer (>10 blood; 3 solid) • Pharma Par
Slide 15: Notable's Volasertib: Compelling & Risk-Reduced
Notable’s Volasertib: Compelling & Risk-Reduced Consistent, Manageable, Strong Compelling Robust Performance Activity Tolerability On PPMP 15
Slide 16: Volasertib: Consistent & Compelling Activity
Volasertib: Consistent & Compelling Activity Consistent RR Major Impact for Responders 35 31% • Multi-year responses 30 27% 25 20 beyond trial duration 15 • Significant, meaningful 10 5 survival increase (Ph2) 0 BI Ph2 BI Ph3 N=89 N=666 16
Slide 17: Volasertib: Manageable & Robust Tolerability
Volasertib: Manageable & Robust Tolerability • Safety database includes > 1400 patients • Data reported by experienced company (Boehringer Ingelheim) • BI post-hoc analysis suggests upsides for clinical profile through – Consistent infectious prophylaxis – Change to weight/BSA-tailored dosing 17
Slide 18: Volasertib: Strong Performance on PPMP
Volasertib: Strong Performance on PPMP PPMP bio-simulation modeled BI results Volasertib in AML 35 31% 30% RR 30 27% 25 20 15 10 Responders Non-Responders (will be enrolled in selective Volasertib trials) 5 0 BI Ph2 BI Ph3 PPMP ex vivo 18
Slide 19: Volasertib on PPMP: Advance To Best-In-Market Profile
Volasertib on PPMP: Advance To Best-In-Market Profile 4 yrs.* Phase 2a Phase 2B Phase 3 FDA Market 30 Non-Selected Patients* 20 Predicted Responders* 150 Predicted Responders* Lower Risk Faster Speed Longer Life vs. traditional trials Less patients needed Drug + PPMP = new IP vs. BI (n=666) 19 *Targ
Slide 20: PPM Pipeline Nears Inflection Points
PPM Pipeline nears Inflection points Ph2A Results Ph2B Results AML AML VBL Merger ClosED Vola Vola Volasertib 3Q 23 4Q 23 1Q 24 2Q 24 3Q 24 4Q 24 1Q 25 Fosciclopirox Fos Fos Ph2a Results Ph2B Results Platform/Drug Platform/Drug AML AML 20 PPM = Predictive Precision Medicine; Target timelines: VOLA =
Slide 21: Notable PPMP: Pole Position for Game-Changing Impact
Notable PPMP: Pole position for game-changing impact Predictive Precision Medicine From hoping to knowing. Predictable Fast and for all. More success, less risk Scalable Beyond genomics Simpler For practice Better 97% Response Rate 21
Slide 22: Notable
* Notable